NEWS

Kevin LaMarche is the Chief Clinical Officer at RareSight, where he leads the clinical program and serves as the key liaison with physicians, regulatory and reimbursement advisors.  Kevin has been a driver of disruptive, early-stage technology in ophthalmology for more than thirty years.  

His clinical career started as an ophthalmic and surgical scrub technician, specializing in corneal and kerato-refractive procedures.  He went on to became Technical Supervisor for Ophthalmology at Massachusetts Eye and Ear Infirmary (MEEI), supporting the resident and fellowship training programs. While managing the refractive surgery centers and corneal research facilities at MEEI, he served as the clinical trainer and speaker for several pioneering refractive companies, including Tomey, EyeSys, ORC, VISX and Summit. 

He transitioned from hospital to industry during the early days of excimer laser technology with Laser Vision Centers and has since been integral to the launch of several paradigm-shifting technologies in Corneal-Refractive, Retina and Glaucoma.  His client portfolio includes Summit Technologies, VISX, Laser Vision Centers, OccuLogix, SOLX, iScience Interventional, Transcend Medical, ForSight Vision 4 (PDS, RPDS & Susvimo Drug Delivery Platform) and ForSight Vision 5 (Helios Drug Delivery Ring) and Iridex Corp. (Transscleral Cyclophotocoagulation).

Kevin’s early work on the Port Delivery System (PDS)—a refillable, sustained-release implant for the treatment of age-related macular degeneration and diabetic macular edema—has helped establish a new paradigm in retinal disease treatment. He currently serves as Senior Director of Clinical and Medical Affairs at Iridex Corporation, alongside his role at RareSight.

Kevin earned a Bachelor of Science in Biology from the Worcester State University.  He resides in Central Massachusetts with his wife of 38 years and has two adult children and four grandchildren.